Loading
The American Cancer Society's yearly count projected that the United States would pass two million new cancer diagnoses in 2024 for the first time, while the cancer death rate kept falling and colorectal cancer rose to become the leading cause of cancer death in men under 50.
Each January the American Cancer Society projects the number of new cancer cases and deaths in the United States and reviews trends in incidence, mortality and survival from national registries. The 2024 report projected 2,001,140 new cancer cases and 611,720 cancer deaths. It reported that the cancer mortality rate had fallen by a third since 1991, averting more than four million deaths, but that incidence was rising for six of the ten most common cancers and shifting towards younger adults, with colorectal cancer now the leading cause of cancer death in men under 50 and the second in women under 50.
This series is the standard reference for US cancer numbers and the source of most headlines about cancer in younger adults. The gap between falling mortality and rising incidence is the argument for both continued treatment advances and stronger prevention and screening.
This edition supplied two widely quoted signals: the first population-level evidence of HPV vaccination preventing cervical cancer in the United States, and the warning that reduced PSA screening was shifting prostate cancer towards later diagnosis.
This edition documented the treatment-driven fall in lung cancer deaths that followed targeted therapy and immunotherapy, a rare case of new drugs visibly moving national mortality statistics.
This edition documented the fastest ever annual fall in US cancer mortality and attributed it in part to targeted therapy and immunotherapy for lung cancer, one of the clearest links between new drugs and national statistics.
This edition is often cited for the disparities finding: progress against cancer in the United States was reaching some communities much more than others.
This edition is widely cited for the early warning about colorectal cancer in younger adults, which later editions confirmed.
One of the most cited editions of the series, used as the reference for US cancer numbers in the mid-2010s.
This edition is cited for the shift of cancer to the leading cause of death in a large part of the United States as heart disease mortality fell faster.
This edition marked twenty years of falling US cancer mortality and is cited for the estimate that more than 1.5 million deaths had been averted.
Shares Siegel 2012: Cancer statistics, 2012, Siegel 2015: Cancer statistics, 2015, Siegel 2016: Cancer statistics, 2016, Siegel 2017: Cancer statistics, 2017.
Shares Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries, Incidence versus prevalence, Mortality, HR-positive / HER2-negative breast cancer.
Shares Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries, Incidence versus prevalence, Mortality, HR-positive / HER2-negative breast cancer.
Shares Incidence versus prevalence, Mortality, HR-positive / HER2-negative breast cancer, Colorectal cancer.
Shares Mortality, Endometrial cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares Mortality, HR-positive / HER2-negative breast cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares Rahib 2014: projecting US cancer incidence and deaths to 2030, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares Incidence versus prevalence, Mortality, Colorectal cancer.